مكتبة

Item request has been placed!

Item request cannot be made.

Processing Request

Academic Journal

An open-label study to explore the optimal design of CYP3A drug-drug interaction clinical trials in healthy Chinese people.

Authors : Chen J; Research Ward, Beijing Friendship Hospital, Capital Medical University, Beijing, China.; Li J

Subjects: Drug Interactions* ; Midazolam*/Midazolam*/Midazolam*/pharmacokinetics ; Midazolam*/Midazolam*/Midazolam*/administration & dosage

Source: Pharmacology research & perspectives [Pharmacol Res Perspect] 2024 Aug; Vol. 12 (4), pp. e1252.Publisher: John Wiley & Sons Ltd, British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics Country of Publication: United States

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

The effect of itraconazole, a strong CYP3A4 inhibitor, on the pharmacokinetics of the first-in-class ACKR3/CXCR7 antagonist, ACT-1004-1239.

Authors : Huynh C; Department of Clinical Pharmacology, Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland.; Department of Pharmaceutical Sciences, Biopharmacy, University of Basel, Basel, Switzerland.

Subjects: Itraconazole*/Itraconazole*/Itraconazole*/pharmacokinetics ; Itraconazole*/Itraconazole*/Itraconazole*/administration & dosage ; Itraconazole*/Itraconazole*/Itraconazole*/pharmacology

Source: Clinical and translational science [Clin Transl Sci] 2024 Jul; Vol. 17 (7), pp. e13883.Publisher: WileyBlackwell Pub Country of Publication: United States NLM ID: 101474067 Publication Model: Print Cited Medium: Internet ISSN:

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

A physiologically-based pharmacokinetic precision dosing approach to manage dasatinib drug-drug interactions.

Authors : Kovar C; Clinical Pharmacy, Saarland University, Saarbrücken, Germany.; Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany.

Subjects: Dasatinib*/Dasatinib*/Dasatinib*/pharmacokinetics ; Dasatinib*/Dasatinib*/Dasatinib*/administration & dosage ; Dasatinib*/Dasatinib*/Dasatinib*/pharmacology

Source: CPT: pharmacometrics & systems pharmacology [CPT Pharmacometrics Syst Pharmacol] 2024 Jul; Vol. 13 (7), pp. 1144-1159. Date of Electronic Publication: 2024 May 01.Publisher: Wiley Country of Publication: United States NLM ID: 101580011 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Tipifarnib physiologically-based pharmacokinetic modeling to assess drug-drug interaction, organ impairment, and biopharmaceutics in healthy subjects and cancer patients.

Authors : Okudaira N; Certara, UK Ltd. (Simcyp Division), Sheffield, UK.; Burt H

Subjects: Drug Interactions* ; Models, Biological* ; Neoplasms*/Neoplasms*/Neoplasms*/drug therapy

Source: CPT: pharmacometrics & systems pharmacology [CPT Pharmacometrics Syst Pharmacol] 2024 Aug; Vol. 13 (8), pp. 1366-1379. Date of Electronic Publication: 2024 May 28.Publisher: Wiley Country of Publication: United States NLM ID: 101580011 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Pharmacokinetics of the Akt Serine/Threonine Protein Kinase Inhibitor, Capivasertib, Administered to Healthy Volunteers in the Presence and Absence of the CYP3A4 Inhibitor Itraconazole.

Authors : Miller C; Clinical Pharmacology and Quantitative Pharmacology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.; Sommavilla R

Subjects: Cytochrome P-450 CYP3A Inhibitors*/Cytochrome P-450 CYP3A Inhibitors*/Cytochrome P-450 CYP3A Inhibitors*/pharmacology ; Itraconazole*/Itraconazole*/Itraconazole*/pharmacokinetics; Humans

Source: Clinical pharmacology in drug development [Clin Pharmacol Drug Dev] 2023 Sep; Vol. 12 (9), pp. 856-862. Date of Electronic Publication: 2023 Jul 14.Publisher: Wiley Country of Publication: United States NLM ID: 101572899 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Physiologically based pharmacokinetic modeling (PBPK) to predict drug-drug interactions for encorafenib. Part II. Prospective predictions in hepatic and renal impaired populations with clinical inhibitors and inducers.

Authors : Kollipara S; KL College of Pharmacy, Koneru Lakshmaiah Education Foundation, Vaddeswaram, Guntur, Andhra Pradesh, India.; Ahmed T

Subjects: Cytochrome P-450 CYP3A*/Cytochrome P-450 CYP3A*/Cytochrome P-450 CYP3A*/metabolism ; Cytochrome P-450 CYP3A Inhibitors*/Cytochrome P-450 CYP3A Inhibitors*/Cytochrome P-450 CYP3A Inhibitors*/pharmacokinetics; Cytochrome P-450 CYP2C19

Source: Xenobiotica; the fate of foreign compounds in biological systems [Xenobiotica] 2023 May; Vol. 53 (5), pp. 339-356. Date of Electronic Publication: 2023 Aug 29.Publisher: Informa Healthcare Country of Publication: England NLM ID: 1306665 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Physiologically based pharmacokinetic modelling to predict drug-drug interactions for encorafenib. Part I. Model building, validation, and prospective predictions with enzyme inhibitors, inducers, and transporter inhibitors.

Authors : Kollipara S; KL College of Pharmacy, Koneru Lakshmaiah Education Foundation, Vaddeswaram, Guntur, Andhra Pradesh, India.; Ahmed T

Subjects: Cytochrome P-450 CYP3A Inhibitors*/Cytochrome P-450 CYP3A Inhibitors*/Cytochrome P-450 CYP3A Inhibitors*/pharmacokinetics ; Diltiazem*; Cytochrome P-450 CYP2C19

Source: Xenobiotica; the fate of foreign compounds in biological systems [Xenobiotica] 2023 May; Vol. 53 (5), pp. 366-381. Date of Electronic Publication: 2023 Sep 04.Publisher: Informa Healthcare Country of Publication: England NLM ID: 1306665 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Tiered approach to evaluate the CYP3A victim and perpetrator drug-drug interaction potential for vonoprazan using PBPK modeling and clinical data to inform labeling.

Authors : Mulford DJ; Phathom Pharmaceuticals, Inc., Buffalo Grove, Illinois, USA.; Ramsden D

Subjects: Cytochrome P-450 CYP3A Inhibitors*/Cytochrome P-450 CYP3A Inhibitors*/Cytochrome P-450 CYP3A Inhibitors*/pharmacokinetics ; Cytochrome P-450 CYP3A Inducers*/Cytochrome P-450 CYP3A Inducers*/Cytochrome P-450 CYP3A Inducers*/pharmacokinetics; Humans

Source: CPT: pharmacometrics & systems pharmacology [CPT Pharmacometrics Syst Pharmacol] 2023 Apr; Vol. 12 (4), pp. 532-544. Date of Electronic Publication: 2023 Mar 10.Publisher: Wiley Country of Publication: United States NLM ID: 101580011 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Understanding CYP3A4 and P-gp mediated drug-drug interactions through PBPK modeling - Case example of pralsetinib.

Authors : Bowman C; Genentech, Inc., South San Francisco, California, USA.; Dolton M

Subjects: Cytochrome P-450 CYP3A*/Cytochrome P-450 CYP3A*/Cytochrome P-450 CYP3A*/metabolism ; Pyrimidines* ; Pyrazoles*

Source: CPT: pharmacometrics & systems pharmacology [CPT Pharmacometrics Syst Pharmacol] 2024 Apr; Vol. 13 (4), pp. 660-672. Date of Electronic Publication: 2024 Mar 13.Publisher: Wiley Country of Publication: United States NLM ID: 101580011 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Evaluation of the drug-drug interaction potential of brigatinib using a physiologically-based pharmacokinetic modeling approach.

Authors : Hanley MJ; Clinical Pharmacology, Takeda Development Center Americas, Inc., Lexington, Massachusetts, USA.; Yeo KR

Subjects: Carcinoma, Non-Small-Cell Lung* ; Lung Neoplasms* ; Organophosphorus Compounds*

Source: CPT: pharmacometrics & systems pharmacology [CPT Pharmacometrics Syst Pharmacol] 2024 Apr; Vol. 13 (4), pp. 624-637. Date of Electronic Publication: 2024 Jan 30.Publisher: Wiley Country of Publication: United States NLM ID: 101580011 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

نتائج البحث

فلترة النتائج

An open-label study to explore the optimal design of CYP3A drug-drug interaction clinical trials in healthy Chinese people.

The effect of itraconazole, a strong CYP3A4 inhibitor, on the pharmacokinetics of the first-in-class ACKR3/CXCR7 antagonist, ACT-1004-1239.

A physiologically-based pharmacokinetic precision dosing approach to manage dasatinib drug-drug interactions.

Tipifarnib physiologically-based pharmacokinetic modeling to assess drug-drug interaction, organ impairment, and biopharmaceutics in healthy subjects and cancer patients.

Pharmacokinetics of the Akt Serine/Threonine Protein Kinase Inhibitor, Capivasertib, Administered to Healthy Volunteers in the Presence and Absence of the CYP3A4 Inhibitor Itraconazole.

Physiologically based pharmacokinetic modeling (PBPK) to predict drug-drug interactions for encorafenib. Part II. Prospective predictions in hepatic and renal impaired populations with clinical inhibitors and inducers.

Physiologically based pharmacokinetic modelling to predict drug-drug interactions for encorafenib. Part I. Model building, validation, and prospective predictions with enzyme inhibitors, inducers, and transporter inhibitors.

Tiered approach to evaluate the CYP3A victim and perpetrator drug-drug interaction potential for vonoprazan using PBPK modeling and clinical data to inform labeling.

Understanding CYP3A4 and P-gp mediated drug-drug interactions through PBPK modeling - Case example of pralsetinib.

Evaluation of the drug-drug interaction potential of brigatinib using a physiologically-based pharmacokinetic modeling approach.

اتصل بنا

اتبع